Drugs / VX-150
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06420765 | May 2024 → Mar 2025 | — | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT05418712 | Jun → Sep 2022 | — | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 24 trials · 3 met primary · 1 missed | ||||||
| Phase 2 | NCT03764072 | Dec 2018 → Jan 2019 | — | Vertex Pharmaceuticals Incorporated | Completed | Missed primary |
| Phase 2 | NCT03304522 | Sep 2017 → Oct 2018 | neuropathy, small fiber | Vertex Pharmaceuticals Incorporated | Completed | Met primary |
| Phase 2 | NCT03206749 | Jun → Dec 2017 | — | Vertex Pharmaceuticals Incorporated | Completed | Met primary |
| Phase 2 | NCT02660424 | Dec 2015 → Aug 2016 | osteoarthritis | Vertex Pharmaceuticals Incorporated | Completed | Met primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2018-12-18 | Vertex Pharmaceuticals Incorporated | Results Vertex Announces Positive Phase 2 Data in Third Proof-of-Concept Study with the NaV1.8 Inhibitor VX-150 vrtx.com ↗
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results of a Phase 2 study of the investigational NaV1.8 inhibitor VX-150 in patients with pain caused by small fiber neuropathy. |
| 2018-02-14 | Vertex Pharmaceuticals Incorporated | Results Vertex Announces Treatment with the NaV1.8 Inhibitor VX-150 Showed Significant Relief of Acute Pain in Phase 2 Study vrtx.com ↗
Treatment with VX-150 showed statistically significant relief of acute pain compared to placebo, as determined by the time-weighted Sum of the Pain Intensity Difference over the first 24 hours of treatment (SPID24), a standard measure of acute pain relief. |
| 2017-01-25 | Vertex Pharmaceuticals Incorporated | Results Vertex Reports Full-Year and Fourth-Quarter 2016 Financial Results vrtx.com ↗
Data from the proof-of-concept study showed statistically significant pain relief with VX-150 and support its further development for the potential treatment of a broad spectrum of pain conditions. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-12-18 | Vertex Pharmaceuticals Incorporated | Vertex Announces Positive Phase 2 Data in Third Proof-of-Concept Study with the NaV1.8 Inhibitor VX-150 vrtx.com ↗ |
| 2018-02-14 | Vertex Pharmaceuticals Incorporated | Vertex Announces Treatment with the NaV1.8 Inhibitor VX-150 Showed Significant Relief of Acute Pain in Phase 2 Study vrtx.com ↗ |
| 2017-01-25 | Vertex Pharmaceuticals Incorporated | Vertex Reports Full-Year and Fourth-Quarter 2016 Financial Results vrtx.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VX-150 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06420765 ↗ |
| Action | Inhibit | “NaV1.8 inhibition” NCT06420765 ↗ |
| Route | Oral | “1250 milligrams (mg) once daily (qd) orally” NCT03304522 ↗ |